Tests time-restricted eating in adults with type 2 diabetes
Tests eating only within a set time window in adults with type 2 diabetes.
Plain-language title generated from the registry record
Registry title: Time Restricted-EAting for Type 2 Diabetes and MEtabolic Health: the TEA TIME Trial
Key facts
- Where
- Toronto, CanadaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT07272460, who can take part
Where in Canada
- Leadership Sinai Centre for DiabetesToronto, CanadaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Mount Sinai Hospital, Canada
- Trial code
- NCT07272460
- Record updated
- 11 February 2026
- Original description
Time-restricted eating - where no food is consumed over a period of time - has been shown to promote weight loss and improve cardio-metabolic function. In individuals with type 2 diabetes, it is also been shown to improve glucose control. The investigators propose a randomized controlled trial to determine whether time-restricted eating is an effective therapeutic strategy that can preserve pancreatic beta-cell function and improve glycemic control early in participants with type 2 diabetes.Read full original descriptionShow less
Time Restricted-eating and Metabolic Health in Patients With Type 2 Diabetes
Time-restricted eating - where no food is consumed over a period of time - has been shown to promote weight loss and improve cardio-metabolic function. In individuals with type 2 diabetes, it is also been shown to improve glucose control. The investigators propose a randomized controlled trial to determine whether time-restricted eating is an effective therapeutic strategy that can preserve pancreatic beta-cell function and improve glycemic control early in participants with type 2 diabetes.
Inclusion: Individuals with previously diagnosed BMI ≥ 25 kg/m2 and type 2 diabetes within preceding 10 years; Age 18 - 75 years inclusive; Stable weight over past 12 weeks (less than 5% change in body weight) (self-reported); Diabetes treatment consisting of lifestyle only or metformin, dipeptidyl peptidase-4 (DPP-4) inhibitor, and sodium-glucose co-transporter 2 (SGLT2) inhibitors either as monotherapy or in combination; Ability to read and understand English.
Exclusion: Current diabetes treatment with insulin, glucagon-like peptide-1 receptor agonists, and/or sulfonylureas; Previous surgical treatment for weight loss such as gastric bypass or gastric band; Malignant neoplasm requiring chemotherapy, surgery, radiation or palliative therapy within the previous 5 years (with the exception of basal cell skin cancer); Concurrent participation in another research study relevant to diabetes and metabolic health; Any history of eating disorder; New York Heart Association class II-IV heart failure; Renal dysfunction as evidenced by estimated glomerular filtration rate < 25 ml/min by CKD-EPI Creatinine Equation; Hepatic disease considered to be clinically significant (includes jaundice, chronic hepatitis, or previous liver transplant) or transaminases >2.5X the upper limit of normal; Use of any other pharmacological treatment for weight-loss; Currently pregnant or lactating; Any other factor likely to limit adherence to the study, in the opinion of the investigators.